Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.

Hermine I Brunner Nicolino RupertoZbigniew ZuberRubén CutticaVladimir KeltsevRicardo M XavierRuben Burgos-VargasInmaculada Calvo PenadesEarl D SilvermanGraciela EspadaManuel Ferrandiz ZavalerYukiko KimuraCarolina DuarteChantal Job-DeslandreRik JoosWendy DouglassSunethra WimalasunderaKamal N BharuchaChris WellsDaniel J LovellAlberto MartiniFabrizio de Benedettinull null

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

Patients treated with TCZ for polyarticular-course JIA showed high-level disease control for up to 2 years. The TCZ safety profile was consistent with that previously reported.

Keyphrases

juvenile idiopathic arthritis
phase iii
open label
phase ii
clinical trial
disease activity
phase ii study
study protocol
double blind
placebo controlled
rheumatoid arthritis
systemic lupus erythematosus
squamous cell carcinoma
rheumatoid arthritis patients
randomized controlled trial